Related Experiment Video
Updated: May 13, 2025
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
Published on: July 4, 2007
Subacute Sclerosing Panencephalitis: Recent Advances in Pathogenesis, Diagnosis, and Treatment
Ravindra Kumar Garg1, Shweta Pandey
1Department of Neurology, King George Medical University, Lucknow, Uttar Pradesh, India.
Abstract:
Subacute sclerosing panencephalitis (SSPE) is a relentless progressive brain disorder caused by the persistent presence of mutated measles virus in the central nervous system. The disease typically develops years after primary measles infection, with the highest risk observed in children infected before the age of 2 years. The global incidence of SSPE is notably higher in low- and middle-income countries and in regions with low measles vaccination coverage. The pathogenesis of SSPE involves viral persistence through mutations in viral proteins, enabling immune evasion and cell-to-cell propagation within the brain. Neuroinflammation, immune-mediated damage, and neuronal loss further contribute to disease progression. Clinical manifestations range from progressive cognitive decline and behavioral changes, along with myoclonus, seizures, movement disorders, visual impairment, and, finally, a vegetative state. Diagnosis is confirmed through cerebrospinal fluid analysis showing elevated antimeasles antibodies, characteristic periodic electroencephalography discharges, and neuroimaging findings like white matter hyperintensities and cerebral atrophy. Treatment remains challenging, with isoprinosine, interferon-α, ribavirin, and newer agents like favipiravir and aprepitant offering new hope. Symptomatic management and palliative care are needed in all patients. SSPE is invariably fatal. Notably, reports of prolonged survival and disease stabilization have been documented, particularly with early and combined therapy. The coronavirus disease 2019 pandemic's adverse impact on measles vaccination rates highlights the urgent need for robust measles immunization campaigns. Future directions involve exploring antiviral fusion peptide inhibitors and artificial intelligence-driven diagnostic tools to improve early detection, treatment efficacy, and outcome prediction in SSPE.
Insights
Subacute sclerosing panencephalitis (SSPE) is a fatal brain disorder caused by persistent measles virus. Early, combined therapy offers hope for prolonged survival and disease stabilization.
Area of Science:
- Neurology
- Virology
- Immunology
Background:
- Subacute sclerosing panencephalitis (SSPE) is a rare, progressive neurological disorder resulting from persistent measles virus infection in the central nervous system.
- It predominantly affects children infected with measles before age two, with higher incidence in regions with low vaccination rates.
- Pathogenesis involves viral mutations, immune evasion, neuroinflammation, and neuronal loss, leading to severe cognitive and motor deficits.
Purpose of the Study:
- To review the pathogenesis, clinical manifestations, diagnostic criteria, and current treatment strategies for SSPE.
- To highlight the challenges in SSPE management and explore emerging therapeutic avenues.
- To emphasize the importance of measles vaccination in SSPE prevention and discuss future research directions.
Main Methods:
- Systematic review of literature on SSPE pathogenesis, clinical presentation, diagnosis, and treatment.
- Analysis of diagnostic markers including cerebrospinal fluid antibodies, EEG patterns, and neuroimaging.
- Evaluation of therapeutic agents and their efficacy, alongside palliative care approaches.
Main Results:
- SSPE diagnosis relies on elevated antimeasles antibodies, characteristic EEG findings, and neuroimaging.
- Current treatments include isoprinosine, interferon-α, ribavirin, favipiravir, and aprepitant, with combined therapy showing promise for prolonged survival.
- Despite being invariably fatal, early intervention and symptomatic management are crucial for improving patient outcomes.
Conclusions:
- SSPE remains a devastating disease, underscoring the critical need for high measles vaccination coverage globally.
- Advances in antiviral therapies and diagnostic tools like AI offer potential for improved early detection and treatment.
- Further research into novel antiviral strategies and predictive models is essential for enhancing SSPE patient outcomes.
More Related Videos
08:17Author Spotlight: Unveiling the Pathway Linking Obesity to Autoimmune Inflammation in Multiple Sclerosis
Published on: February 23, 2024
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
